{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:57:11Z","timestamp":1788217031413,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1148060"],"award-info":[{"award-number":["1148060"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The aim of this study was to determine the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and warfarin in adults with atrial fibrillation (AF) by level of kidney function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We pooled findings from five retrospective cohorts (2011\u201318) across Australia and Canada of adults with; a new dispensation for a DOAC or warfarin, an AF diagnosis, and a measure of baseline estimated glomerular filtration rate (eGFR). The outcomes of interest, within 1 year from the cohort entry date, were: (1) the composite of all-cause death, first hospitalization for ischaemic stroke, or transient ischaemic attack (effectiveness), and (2) first hospitalization for major bleeding defined as an intracranial, upper or lower gastrointestinal, or other bleeding (safety). Cox models were used to examine the association of a DOAC vs. warfarin with outcomes, after 1:1 matching via a propensity score. Kidney function was categorized as eGFR\u00a0\u226560, 45\u201359, 30\u201344, and &amp;lt;30\u00a0mL\/min\/1.73\u00a0m2. A total of 74\u00a0542 patients were included in the matched analysis. DOAC initiation was associated with greater or similar effectiveness compared with warfarin initiation across all eGFR categories [pooled HRs (95% CIs) for eGFR categories: 0.74(0.69\u20130.79), 0.76(0.54\u20131.07), 0.68(0.61\u20130.75) and 0.86(0.76\u20130.98)], respectively. DOAC initiation was associated with lower or similar risk of major bleeding than warfarin initiation [pooled HRs (95% CIs): 0.75(0.65\u20130.86), 0.81(0.65\u20131.01), 0.82(0.66\u20131.02), and 0.71(0.52\u20130.99), respectively). Associations between DOAC initiation, compared with warfarin initiation, and study outcomes were not modified by eGFR category.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>DOAC use, compared with warfarin use, was associated with a lower or similar risk of all-cause death, ischaemic stroke, and transient ischaemic attack and also a lower or similar risk of major bleeding across all levels of kidney function.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcac069","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T12:45:54Z","timestamp":1666615554000},"page":"621-631","source":"Crossref","is-referenced-by-count":11,"title":["Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-7535","authenticated-orcid":false,"given":"Min","family":"Jun","sequence":"first","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Sydney , Newtown, NSW 2042 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Scaria","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Sydney , Newtown, NSW 2042 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Andrade","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver General Hospital , Vancouver, BC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V","family":"Badve","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Sydney , Newtown, NSW 2042 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Birks","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver General Hospital , Vancouver, BC , Canada"},{"name":"Division of Nephrology, University of British Columbia , Vancouver, BC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E","family":"Bota","sequence":"additional","affiliation":[{"name":"ICES , ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campain","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Sydney , Newtown, NSW 2042 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ognjenka","family":"Djurdjev","sequence":"additional","affiliation":[{"name":"BC Renal , Vancouver, BC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X","family":"Garg","sequence":"additional","affiliation":[{"name":"ICES , ON , Canada"},{"name":"Department of Medicine, Epidemiology and Biostatistics, Western University , London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Ha","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Sydney , Newtown, NSW 2042 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziv","family":"Harel","sequence":"additional","affiliation":[{"name":"Division of Nephrology, St. Michael's Hospital , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Hemmelgarn","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, University of Alberta , Edmonton, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-5350","authenticated-orcid":false,"given":"Carinna","family":"Hockham","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T","family":"James","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, Division of Nephrology, University of Calgary , Calgary AB , Canada"},{"name":"Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary , AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J","family":"Jardine","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver General Hospital , Vancouver, BC , Canada"},{"name":"Division of Nephrology, University of British Columbia , Vancouver, BC , Canada"},{"name":"BC Renal , Vancouver, BC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McArthur","sequence":"additional","affiliation":[{"name":"ICES , ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ravani","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, Division of Nephrology, University of Calgary , Calgary AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Shao","sequence":"additional","affiliation":[{"name":"BC Renal , Vancouver, BC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M","family":"Sood","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Research Institute and Department of Medicine, The Ottawa Hospital , Ottawa, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Tan","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, Division of Nephrology, University of Calgary , Calgary AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba , Winnipeg, MB , Canada"},{"name":"Seven Oaks Hospital Chronic Disease Innovation Centre , Winnipeg, MB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-0358","authenticated-orcid":false,"given":"Reid","family":"Whitlock","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba , Winnipeg, MB , Canada"},{"name":"Seven Oaks Hospital Chronic Disease Innovation Centre , Winnipeg, MB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gallagher","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Sydney , Newtown, NSW 2042 , Australia"},{"name":"Liverpool Clinical School, UNSW Sydney , Sydney, NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2023091205381186600_bib1","first-page":"837","article-title":"Worldwide epidemiology of atrial fibrillation","volume":"129","author":"Chugh","year":"2014"},{"key":"2023091205381186600_bib2","first-page":"2381","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation","volume":"126","author":"Dentali","year":"2012"},{"key":"2023091205381186600_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet North Am Ed"},{"key":"2023091205381186600_bib4","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"2023091205381186600_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2023091205381186600_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023091205381186600_bib7","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2023091205381186600_bib8","doi-asserted-by":"crossref","first-page":"h246","DOI":"10.1136\/bmj.h246","article-title":"The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study","volume":"350","author":"Jun","year":"2015","journal-title":"BMJ"},{"key":"2023091205381186600_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-2004-835678","article-title":"Platelet Dysfunction in Renal Failure","volume":"30","author":"Boccardo","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"2023091205381186600_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.blre.2011.07.001","article-title":"Bleeding and thrombotic complications of kidney disease","volume":"25","author":"Pavord","year":"2011","journal-title":"Blood Rev"},{"key":"2023091205381186600_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2215\/CJN.02170218","article-title":"Clinical pharmacology of oral nticoagulants in Patients with Kidney Disease","volume":"14","author":"Jain","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023091205381186600_bib12","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K Anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023091205381186600_bib13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2023091205381186600_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2023091205381186600_bib15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2023091205381186600_bib16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2023091205381186600_bib17","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1080\/03007995.2017.1339674","article-title":"Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence","volume":"33","author":"Weir","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2023091205381186600_bib18","doi-asserted-by":"crossref","first-page":"e019638","DOI":"10.1136\/bmjopen-2017-019638","article-title":"Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study","volume":"8","author":"Loo","year":"2018","journal-title":"BMJ open"},{"key":"2023091205381186600_bib19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2215\/CJN.13811217","article-title":"Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation","volume":"13","author":"Shin","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023091205381186600_bib20","doi-asserted-by":"crossref","first-page":"e15646","DOI":"10.2196\/15646","article-title":"EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): protocol for an Australian Linked Cohort Study","volume":"9","author":"Foote","year":"2020","journal-title":"JMIR Research Protocols"},{"key":"2023091205381186600_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ije\/dym184","article-title":"Cohort profile: the 45 and up study","volume":"37","author":"45, Collaborators US","year":"2007","journal-title":"Int J Epidemiol"},{"key":"2023091205381186600_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/pds.2317","article-title":"A systematic review of validated methods for identifying atrial fibrillation using administrative data","volume":"21","author":"Jensen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023091205381186600_bib23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/CLEP.S206267","article-title":"Sensitivity, specificity, positive and negative predictive values of identifying atrial fibrillation using administrative data: a systematic review and meta-analysis","volume":"11","author":"Yao","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"2023091205381186600_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023091205381186600_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2023091205381186600_bib26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2023091205381186600_bib27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and Stroke Risk Factors Using International Classification of Diseases, Revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"key":"2023091205381186600_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.thromres.2005.06.015","article-title":"Accuracy of coding for possible warfarin complications in hospital discharge abstracts","volume":"118","author":"Arnason","year":"2006","journal-title":"Thromb Res"},{"key":"2023091205381186600_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2023091205381186600_bib30","first-page":"2084","article-title":"A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use","volume":"25","author":"Austin","year":"2006"},{"key":"2023091205381186600_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2023091205381186600_bib32","doi-asserted-by":"crossref","first-page":"e006515","DOI":"10.1161\/CIRCOUTCOMES.120.006515","article-title":"Comparative effectiveness and safety of oral anticoagulants across kidney function in patients with atrial fibrillation","volume":"13","author":"Yao","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2023091205381186600_bib33","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamaneurol.2019.2099","article-title":"Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with warial fibrillation and ischemic stroke: findings from the Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study","volume":"76","author":"Xian","year":"2019","journal-title":"JAMA Neurol"},{"key":"2023091205381186600_bib34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2023091205381186600_bib35","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"issue":"(9)","key":"2023091205381186600_bib36","first-page":"961970","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"2023091205381186600_bib37","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"2023091205381186600_bib38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2013040361","article-title":"Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD","volume":"25","author":"Harel","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2023091205381186600_bib39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med"},{"key":"2023091205381186600_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000445328","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis","volume":"43","author":"Dias","year":"2016","journal-title":"Am J Nephrol"},{"key":"2023091205381186600_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","article-title":"Dose-finding study of rivaroxaban in hemodialysis patients","volume":"66","author":"De Vriese","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2023091205381186600_bib42","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2023091205381186600_bib43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial","volume":"1","author":"Hijazi","year":"2016","journal-title":"JAMA Cardiology"},{"key":"2023091205381186600_bib44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"key":"2023091205381186600_bib45","article-title":"Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study","volume":"353","author":"Wang","year":"2016","journal-title":"BMJ"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcac069\/47161678\/qcac069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/9\/6\/621\/51507094\/qcac069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/9\/6\/621\/51507094\/qcac069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T05:52:57Z","timestamp":1694497977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/9\/6\/621\/6776011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,10,27]]},"published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcac069","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2022,10,27]]}}}